# Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes

> **NCT06224803** · NA · COMPLETED · sponsor: **Global Preventive Medicine Biotech Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Type II Diabetes

## Interventions

- **DIETARY_SUPPLEMENT:** Compound plant extracts
- **DIETARY_SUPPLEMENT:** Indigestible dextrin

## Key facts

- **NCT ID:** NCT06224803
- **Lead sponsor:** Global Preventive Medicine Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-26
- **Primary completion:** 2021-07-21
- **Final completion:** 2022-01-18
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224803, "Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06224803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*